Cushing's Syndrome – Pipeline Review, Q2 2011
Cushing's Syndrome - Pipeline Review, Q2 2011
Reference Code: GMDHC1008IDB
Publication Date: April 2011
Cushing's Syndrome – Pipeline Review, Q2 2011 GMDHC1008IDB / Pub April 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Cushing's Syndrome – Pipeline Review, Q2 2011
Ta b le o f Co n te n ts
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cushing's Syndrome Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Cushing's Syndrome 7
Cushing's Syndrome Therapeutics under Development by Companies 9
Cushing's Syndrome Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Cushing's Syndrome Therapeutics - Products under Development by Companies 16
Cushing's Syndrome Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in Cushing's Syndrome Therapeutics Development 18
Ipsen S.A. 18
Novartis AG 18
Corcept Therapeutics Incorporated 19
Samaritan Pharmaceuticals, Inc. 19
HRA Pharma, SA 20
Cushing's Syndrome - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Pasireotide - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Mifedren - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Corlux - Drug Profile 29
Product Description